Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions
INTRODUCTION: Targeted therapy is used to treat lung adenocarcinoma caused by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain and rare subtypes (<5%) of non-small cell lung cancer. These subtypes include fusion oncoproteins like anaplastic lymphoma kinase (ALK), ROS1, rearranged during transfection (RET), and other receptor tyrosine kinases (RTKs). The use of diverse selective oral inhibitors, including those targeting rat sarcoma viral oncogene homolog (KRAS) mutations, has significantly improved clinical responses, extending progression-free and overall survival.
AREAS COVERED: Resistance remains a critical issue in lung adenocarcinoma, notably in EGFR mutant, echinoderm microtubule associated protein-like 4 (EML4)-ALK fusion, and KRAS mutant tumors, often associated with epithelial-to-mesenchymal transition (EMT).
EXPERT OPINION: Despite advancements in next generation EGFR inhibitors and EML4-ALK therapies with enhanced brain penetrance and identifying resistance mutations, overcoming resistance has not been abated. Various strategies are being explored to overcome this issue to achieve prolonged cancer remission and delay resistance. Targeting yes-associated protein (YAP) and the mechanisms associated with YAP activation through Hippo-dependent or independent pathways, is desirable. Additionally, the exploration of liquid-liquid phase separation in fusion oncoproteins forming condensates in the cytoplasm for oncogenic signaling is a promising field for the development of new treatments.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Expert opinion on investigational drugs - 33(2024), 3 vom: 19. März, Seite 171-182 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rosell, Rafael [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/13543784.2024.2320710 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368627284 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368627284 | ||
003 | DE-627 | ||
005 | 20240311232348.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240219s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/13543784.2024.2320710 |2 doi | |
028 | 5 | 2 | |a pubmed24n1323.xml |
035 | |a (DE-627)NLM368627284 | ||
035 | |a (NLM)38372666 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rosell, Rafael |e verfasserin |4 aut | |
245 | 1 | 0 | |a Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.03.2024 | ||
500 | |a Date Revised 11.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a INTRODUCTION: Targeted therapy is used to treat lung adenocarcinoma caused by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain and rare subtypes (<5%) of non-small cell lung cancer. These subtypes include fusion oncoproteins like anaplastic lymphoma kinase (ALK), ROS1, rearranged during transfection (RET), and other receptor tyrosine kinases (RTKs). The use of diverse selective oral inhibitors, including those targeting rat sarcoma viral oncogene homolog (KRAS) mutations, has significantly improved clinical responses, extending progression-free and overall survival | ||
520 | |a AREAS COVERED: Resistance remains a critical issue in lung adenocarcinoma, notably in EGFR mutant, echinoderm microtubule associated protein-like 4 (EML4)-ALK fusion, and KRAS mutant tumors, often associated with epithelial-to-mesenchymal transition (EMT) | ||
520 | |a EXPERT OPINION: Despite advancements in next generation EGFR inhibitors and EML4-ALK therapies with enhanced brain penetrance and identifying resistance mutations, overcoming resistance has not been abated. Various strategies are being explored to overcome this issue to achieve prolonged cancer remission and delay resistance. Targeting yes-associated protein (YAP) and the mechanisms associated with YAP activation through Hippo-dependent or independent pathways, is desirable. Additionally, the exploration of liquid-liquid phase separation in fusion oncoproteins forming condensates in the cytoplasm for oncogenic signaling is a promising field for the development of new treatments | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a EGFR mutations | |
650 | 4 | |a EML4-ALK fusions | |
650 | 4 | |a KRAS mutations | |
650 | 4 | |a N-terminal fusion partners | |
650 | 4 | |a liquid-like condensates | |
650 | 4 | |a lung adenocarcinoma | |
650 | 4 | |a yes-associated protein (YAP) | |
650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
650 | 7 | |a EC 3.6.5.2 |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
650 | 7 | |a Receptor Protein-Tyrosine Kinases |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a ErbB Receptors |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Oncogene Proteins, Fusion |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
700 | 1 | |a Pedraz-Valdunciel, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Jain, Anisha |e verfasserin |4 aut | |
700 | 1 | |a Shivamallu, Chandan |e verfasserin |4 aut | |
700 | 1 | |a Aguilar, Andrés |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 33(2024), 3 vom: 19. März, Seite 171-182 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2024 |g number:3 |g day:19 |g month:03 |g pages:171-182 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2024.2320710 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 33 |j 2024 |e 3 |b 19 |c 03 |h 171-182 |